DEAD box proteins, characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD), are putative RNA helicases. They are implicated in a number of cellular processes involving alteration of RNA secondary structure such as translation initiation, nuclear and mitochondrial splicing, and ribosome and spliceosome assembly. Based on their distribution patterns, some members of this family are believed to be involved in embryogenesis, spermatogenesis, and cellular growth and division. This gene encodes a DEAD box protein that is upregulated in response to treatment with beta-interferon and a protein kinase C-activating compound, mezerein. Irreversible reprogramming of melanomas can be achieved by treatment with both these agents; treatment with either agent alone only achieves reversible differentiation. Genetic variation in this gene is associated with diabetes mellitus insulin-dependent type 19. [provided by RefSeq, Jul 2012]
Function
ATP binding; DNA binding; double-stranded RNA binding; double-stranded RNA binding; helicase activity; protein binding; ribonucleoprotein complex binding; single-stranded RNA binding; zinc ion binding
Synonyms
IFIH1; interferon induced with helicase C domain 1; AGS7; Hlcd; MDA5; MDA-5; RLR-2; IDDM19; interferon-induced helicase C domain-containing protein 1; helicard; CADM-140 autoantigen; RIG-I-like receptor 2; helicase with 2 CARD domains; RNA helicase-DEAD box protein 116; murabutide down-regulated protein; DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide; melanoma differentiation associated protein-5; melanoma differentiation-associated protein 5; clinically amyopathic dermatomyositis autoantigen 140 kDa
Citations
Publication ()
Have you cited CDBP5739 in a publication? Let us know and earn a reward for your research.
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.